Summary by Futu AI
SAI PHARMACEUTICALS ANNOUNCED ON 19 APRIL 2024 THAT ITS EXECUTIVE OFFICER, ZHAO HUNG, PURSUANT TO RULE 22 OF THE HONG KONG CODE OF COMPANIES ACQUISITIONS AND MERGERS, CONDUCTED A SHARE OPTION TRANSACTION BY AGREEMENT ON 18 APRIL 2024. The transaction involves 2,000,000 share options with a period of exercise from 18 April 2030 at an exercise price of HK$7.8920 per share. After this transaction, Zhao Hong's total shares of Caisang Pharmaceuticals reached 19,098,742 shares. The transaction was conducted under the Sai Sai Pharmaceutical Company's Share Option Incentive Scheme and was conducted for its own account.